Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Blood-based circulating tumor DNA mutations as a diagnostic and prognostic biomarker for lung cancer.

Cancer - 15 Apr 2020

Leung Maria, Freidin Maxim B, Freydina Daria V, Von Crease Charlotte, De Sousa Paulo, Barbosa Monica T, Nicholson Andrew G, Lim Eric

Abstract excerpt

BACKGROUND: The objectives of the current study were to develop an initial blood-based circulating tumor DNA (ctDNA) gene signature and to validate the clinical test performance in patients with early primary and secondary lung cancer. METHODS: Between January 2009 and October 2014, a total of 211 patients with known or suspected lung cancer donated their blood prior to surgery and were followed up to May 2018....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasm Staging

Share to Neoplastic Cells, Circulating

Share to Prognosis

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 31999831
DOI: 10.1002/cncr.32699

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Blood-based circulating tumor DNA mutations as a diagnostic and prognostic biomarker for lung cancer.PMID 31999831Read ↗

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.Semantic proximity Read ↗

Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient ManagementSemantic proximity Read ↗

Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patientsSemantic proximity Read ↗

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.Semantic proximity Read ↗

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.Semantic proximity Read ↗

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.Semantic proximity Read ↗

The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis.Semantic proximity Read ↗

Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response.Semantic proximity Read ↗

The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies.Semantic proximity Read ↗

Analysis of tumor-derived DNA in plasma and bone marrow fluid in lung cancer patients.Semantic proximity Read ↗

Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.